PRKAB1 and PRKAG2-related cardiomyopathy: Reduced activation of AMPK has been reported to be a causative factor of myocardial hypertrophy and arrhythmias, and targeting the AMPK pathway has thus been shown to have therapeutic benefits in patients with PRKAG2 syndrome, a metabolic condition that causes an HCM phenotype [23].